PRO-ADM AS MONITORING MARKER OF THERAPY FOR CRITICALLY ILL PATIENTS Russian patent published in 2022 - IPC G01N33/68 G01N33/74 

FIELD: medicine; clinical and laboratory diagnostics.

SUBSTANCE: invention relates to medicine, namely to clinical and laboratory diagnostics; it can be used for prediction of subsequent undesirable phenomenon in a patient’s health condition. A sample from the specified patient is provided, while the patient is diagnosed as critically ill, and medical treatment has been started. The sample is isolated from the patient’s body after diagnosis and beginning of the treatment. A level of proadrenomedullin (hereinafter – proADM) or its fragment (fragments) is determined in the specified sample. A low level of severity of proADM or its fragment (fragments), determined in the sample, of less than 4 nmol/l indicates the absence of the subsequent undesirable phenomenon. A high level of severity of proADM or its fragment (fragments), determined in the sample, of more than 6.5 nmol/l indicates the subsequent undesirable phenomenon. A level of procalcitonin (hereinafter – PCT) or its fragment (fragments) is additionally determined in the sample with subsequent prediction of the undesirable phenomenon.

EFFECT: method provides for a possibility of prediction of a subsequent undesirable phenomenon in a patient’s health condition, which is: death, new infection, organ failure, and/or deterioration of clinical symptoms, due to determination in a sample of a level of proADM or its fragment (fragments) and, optionally, a level of PCT or its fragment (fragments).

19 cl, 32 tbl, 10 ex